Takayasu  ||| S:0 E:9 ||| JJ
arteritis ||| S:9 E:18 ||| NN
:  ||| S:18 E:20 ||| :
epidemiological ||| S:20 E:35 ||| CD
,  ||| S:35 E:37 ||| ,
clinical ||| S:37 E:45 ||| JJ
,  ||| S:45 E:47 ||| ,
and  ||| S:47 E:51 ||| CC
immunogenetic  ||| S:51 E:65 ||| JJ
features  ||| S:65 E:74 ||| NNS
in  ||| S:74 E:77 ||| IN
Greece  ||| S:77 E:84 ||| NNP
Takayasu  ||| S:84 E:93 ||| NNP
arteritis  ||| S:93 E:103 ||| NNS
( ||| S:103 E:104 ||| -LRB-
TA ||| S:104 E:106 ||| NNP
)  ||| S:106 E:108 ||| -RRB-
is  ||| S:108 E:111 ||| VBZ
an  ||| S:111 E:114 ||| DT
uncommon  ||| S:114 E:123 ||| JJ
disease  ||| S:123 E:131 ||| NN
with  ||| S:131 E:136 ||| IN
clinical  ||| S:136 E:145 ||| JJ
heterogeneity  ||| S:145 E:159 ||| NN
across  ||| S:159 E:166 ||| IN
different  ||| S:166 E:176 ||| JJ
ethnic  ||| S:176 E:183 ||| JJ
groups ||| S:183 E:189 ||| NNS
.  ||| S:189 E:191 ||| .
We  ||| S:191 E:194 ||| PRP
aimed  ||| S:194 E:200 ||| VBD
to  ||| S:200 E:203 ||| TO
evaluate  ||| S:203 E:212 ||| VB
the  ||| S:212 E:216 ||| DT
epidemiological ||| S:216 E:231 ||| NN
,  ||| S:231 E:233 ||| ,
clinical ||| S:233 E:241 ||| JJ
,  ||| S:241 E:243 ||| ,
and  ||| S:243 E:247 ||| CC
immuno-genetic  ||| S:247 E:262 ||| JJ
features  ||| S:262 E:271 ||| NNS
of  ||| S:271 E:274 ||| IN
TA  ||| S:274 E:277 ||| NNP
in  ||| S:277 E:280 ||| IN
Greece ||| S:280 E:286 ||| NNP
.  ||| S:286 E:288 ||| .
Demographic ||| S:288 E:299 ||| NNP
,  ||| S:299 E:301 ||| ,
clinical ||| S:301 E:309 ||| JJ
,  ||| S:309 E:311 ||| ,
laboratory ||| S:311 E:321 ||| NN
,  ||| S:321 E:323 ||| ,
angiographic ||| S:323 E:335 ||| NN
,  ||| S:335 E:337 ||| ,
and  ||| S:337 E:341 ||| CC
therapeutic  ||| S:341 E:353 ||| JJ
data  ||| S:353 E:358 ||| NNS
of  ||| S:358 E:361 ||| IN
42  ||| S:361 E:364 ||| CD
patients  ||| S:364 E:373 ||| NNS
from  ||| S:373 E:378 ||| IN
4  ||| S:378 E:380 ||| CD
large  ||| S:380 E:386 ||| JJ
referral  ||| S:386 E:395 ||| NN
centers  ||| S:395 E:403 ||| NNS
were  ||| S:403 E:408 ||| VBD
retrieved ||| S:408 E:417 ||| VBN
.  ||| S:417 E:419 ||| .
Serology  ||| S:419 E:428 ||| NNP
and  ||| S:428 E:432 ||| CC
Human  ||| S:432 E:438 ||| NNP
Lymphocyte  ||| S:438 E:449 ||| NNP
Antigen  ||| S:449 E:457 ||| NNP
( ||| S:457 E:458 ||| -LRB-
HLA ||| S:458 E:461 ||| NNP
)  ||| S:461 E:463 ||| -RRB-
typing  ||| S:463 E:470 ||| NN
was  ||| S:470 E:474 ||| VBD
performed  ||| S:474 E:484 ||| VBN
in  ||| S:484 E:487 ||| IN
22  ||| S:487 E:490 ||| CD
patients ||| S:490 E:498 ||| NNS
.  ||| S:498 E:500 ||| .
We  ||| S:500 E:503 ||| PRP
studied  ||| S:503 E:511 ||| VBD
37  ||| S:511 E:514 ||| CD
women  ||| S:514 E:520 ||| NNS
and  ||| S:520 E:524 ||| CC
5  ||| S:524 E:526 ||| CD
men  ||| S:526 E:530 ||| NNS
with  ||| S:530 E:535 ||| IN
a  ||| S:535 E:537 ||| DT
median  ||| S:537 E:544 ||| JJ
age  ||| S:544 E:548 ||| NN
of  ||| S:548 E:551 ||| IN
31  ||| S:551 E:554 ||| CD
years  ||| S:554 E:560 ||| NNS
at  ||| S:560 E:563 ||| IN
disease  ||| S:563 E:571 ||| NN
onset ||| S:571 E:576 ||| NN
.  ||| S:576 E:578 ||| .
Median  ||| S:578 E:585 ||| JJ
delay  ||| S:585 E:591 ||| NN
in  ||| S:591 E:594 ||| IN
diagnosis  ||| S:594 E:604 ||| NN
was  ||| S:604 E:608 ||| VBD
24  ||| S:608 E:611 ||| CD
months  ||| S:611 E:618 ||| NNS
and  ||| S:618 E:622 ||| CC
median  ||| S:622 E:629 ||| JJ
follow-up  ||| S:629 E:639 ||| NN
was  ||| S:639 E:643 ||| VBD
47  ||| S:643 E:646 ||| CD
months  ||| S:646 E:653 ||| NNS
( ||| S:653 E:654 ||| -LRB-
range  ||| S:654 E:660 ||| NN
0-178 ||| S:660 E:665 ||| CD
) ||| S:665 E:666 ||| -RRB-
.  ||| S:666 E:668 ||| .
Constitutional  ||| S:668 E:683 ||| JJ
or  ||| S:683 E:686 ||| CC
musculoskeletal  ||| S:686 E:702 ||| JJ
symptoms  ||| S:702 E:711 ||| NNS
were  ||| S:711 E:716 ||| VBD
present  ||| S:716 E:724 ||| JJ
in  ||| S:724 E:727 ||| IN
86 ||| S:727 E:729 ||| CD
% ||| S:729 E:730 ||| NN
,  ||| S:730 E:732 ||| ,
especially  ||| S:732 E:743 ||| RB
early  ||| S:743 E:749 ||| RB
in  ||| S:749 E:752 ||| IN
the  ||| S:752 E:756 ||| DT
disease  ||| S:756 E:764 ||| NN
course ||| S:764 E:770 ||| NN
.  ||| S:770 E:772 ||| .
Vascular  ||| S:772 E:781 ||| JJ
findings  ||| S:781 E:790 ||| NNS
were  ||| S:790 E:795 ||| VBD
universal  ||| S:795 E:805 ||| JJ
with  ||| S:805 E:810 ||| IN
reduced  ||| S:810 E:818 ||| JJ
or  ||| S:818 E:821 ||| CC
absent  ||| S:821 E:828 ||| JJ
pulse  ||| S:828 E:834 ||| NN
being  ||| S:834 E:840 ||| VBG
the  ||| S:840 E:844 ||| DT
most  ||| S:844 E:849 ||| RBS
common  ||| S:849 E:856 ||| JJ
manifestation  ||| S:856 E:870 ||| NNS
( ||| S:870 E:871 ||| -LRB-
98 ||| S:871 E:873 ||| CD
% ||| S:873 E:874 ||| NN
) ||| S:874 E:875 ||| -RRB-
.  ||| S:875 E:877 ||| .
Hypertension  ||| S:877 E:890 ||| NNP
was  ||| S:890 E:894 ||| VBD
frequent  ||| S:894 E:903 ||| JJ
( ||| S:903 E:904 ||| -LRB-
78 ||| S:904 E:906 ||| CD
% ||| S:906 E:907 ||| NN
) ||| S:907 E:908 ||| -RRB-
.  ||| S:908 E:910 ||| .
Extensive  ||| S:910 E:920 ||| JJ
disease  ||| S:920 E:928 ||| NN
prevailed  ||| S:928 E:938 ||| NNS
and  ||| S:938 E:942 ||| CC
stenotic  ||| S:942 E:951 ||| JJ
lesions  ||| S:951 E:959 ||| NNS
were  ||| S:959 E:964 ||| VBD
more  ||| S:964 E:969 ||| RBR
common  ||| S:969 E:976 ||| JJ
than  ||| S:976 E:981 ||| IN
aneurysms  ||| S:981 E:991 ||| NNS
( ||| S:991 E:992 ||| -LRB-
95 ||| S:992 E:994 ||| CD
%  ||| S:994 E:996 ||| NN
vs.  ||| S:996 E:1000 ||| IN
40 ||| S:1000 E:1002 ||| CD
% ||| S:1002 E:1003 ||| NN
) ||| S:1003 E:1004 ||| -RRB-
.  ||| S:1004 E:1006 ||| .
Erythrocyte  ||| S:1006 E:1018 ||| JJ
sedimentation  ||| S:1018 E:1032 ||| JJ
rate  ||| S:1032 E:1037 ||| NN
and  ||| S:1037 E:1041 ||| CC
C-reactive  ||| S:1041 E:1052 ||| JJ
protein  ||| S:1052 E:1060 ||| NN
showed  ||| S:1060 E:1067 ||| VBD
modest  ||| S:1067 E:1074 ||| JJ
correlation  ||| S:1074 E:1086 ||| NN
with  ||| S:1086 E:1091 ||| IN
disease  ||| S:1091 E:1099 ||| NN
activity ||| S:1099 E:1107 ||| NN
.  ||| S:1107 E:1109 ||| .
HLA-B52  ||| S:1109 E:1117 ||| NNP
was  ||| S:1117 E:1121 ||| VBD
expressed  ||| S:1121 E:1131 ||| VBN
by  ||| S:1131 E:1134 ||| IN
37 ||| S:1134 E:1136 ||| CD
%  ||| S:1136 E:1138 ||| NN
of  ||| S:1138 E:1141 ||| IN
the  ||| S:1141 E:1145 ||| DT
patients  ||| S:1145 E:1154 ||| NNS
vs.  ||| S:1154 E:1158 ||| IN
2.4 ||| S:1158 E:1161 ||| CD
%  ||| S:1161 E:1163 ||| NN
of  ||| S:1163 E:1166 ||| IN
the  ||| S:1166 E:1170 ||| DT
controls  ||| S:1170 E:1179 ||| NNS
( ||| S:1179 E:1180 ||| -LRB-
p  ||| S:1180 E:1181 ||| FW
< ||| S:1181 E:1182 ||| SYM
0.001 ||| S:1182 E:1187 ||| FW
) ||| S:1187 E:1188 ||| -RRB-
.  ||| S:1188 E:1190 ||| .
Glucocorticoids  ||| S:1190 E:1206 ||| NNP
and  ||| S:1206 E:1210 ||| CC
cytotoxic  ||| S:1210 E:1220 ||| JJ
agents  ||| S:1220 E:1227 ||| NNS
were  ||| S:1227 E:1232 ||| VBD
used  ||| S:1232 E:1237 ||| VBN
in  ||| S:1237 E:1240 ||| IN
most  ||| S:1240 E:1245 ||| JJS
patients  ||| S:1245 E:1254 ||| NNS
with  ||| S:1254 E:1259 ||| IN
remission  ||| S:1259 E:1269 ||| JJ
rates  ||| S:1269 E:1275 ||| NNS
of  ||| S:1275 E:1278 ||| IN
83 ||| S:1278 E:1280 ||| CD
% ||| S:1280 E:1281 ||| NN
.  ||| S:1281 E:1283 ||| .
A  ||| S:1283 E:1285 ||| DT
total  ||| S:1285 E:1291 ||| NN
of  ||| S:1291 E:1294 ||| IN
42  ||| S:1294 E:1297 ||| CD
surgical  ||| S:1297 E:1306 ||| JJ
procedures  ||| S:1306 E:1317 ||| NNS
were  ||| S:1317 E:1322 ||| VBD
performed  ||| S:1322 E:1332 ||| VBN
with  ||| S:1332 E:1337 ||| IN
success  ||| S:1337 E:1345 ||| NN
rates  ||| S:1345 E:1351 ||| NNS
of  ||| S:1351 E:1354 ||| IN
87 ||| S:1354 E:1356 ||| CD
% ||| S:1356 E:1357 ||| NN
.  ||| S:1357 E:1359 ||| .
TA  ||| S:1359 E:1362 ||| NNP
in  ||| S:1362 E:1365 ||| IN
Greece  ||| S:1365 E:1372 ||| NNP
clinically  ||| S:1372 E:1383 ||| NN
and  ||| S:1383 E:1387 ||| CC
epidemiologically  ||| S:1387 E:1405 ||| NN
resembles  ||| S:1405 E:1415 ||| VBZ
the  ||| S:1415 E:1419 ||| DT
pattern  ||| S:1419 E:1427 ||| NN
of  ||| S:1427 E:1430 ||| IN
disease  ||| S:1430 E:1438 ||| NN
in  ||| S:1438 E:1441 ||| IN
Japan  ||| S:1441 E:1447 ||| NNP
and  ||| S:1447 E:1451 ||| CC
the  ||| S:1451 E:1455 ||| DT
Western  ||| S:1455 E:1463 ||| JJ
hemisphere ||| S:1463 E:1473 ||| NN
.  ||| S:1473 E:1475 ||| .
There  ||| S:1475 E:1481 ||| EX
is  ||| S:1481 E:1484 ||| VBZ
considerable  ||| S:1484 E:1497 ||| JJ
delay  ||| S:1497 E:1503 ||| NN
in  ||| S:1503 E:1506 ||| IN
diagnosis ||| S:1506 E:1515 ||| NN
,  ||| S:1515 E:1517 ||| ,
which  ||| S:1517 E:1523 ||| WDT
may  ||| S:1523 E:1527 ||| MD
partially  ||| S:1527 E:1537 ||| RB
reflect  ||| S:1537 E:1545 ||| VB
failure  ||| S:1545 E:1553 ||| NN
to  ||| S:1553 E:1556 ||| TO
recognize  ||| S:1556 E:1566 ||| VB
a  ||| S:1566 E:1568 ||| DT
rare  ||| S:1568 E:1573 ||| JJ
disease ||| S:1573 E:1580 ||| NN
.  ||| S:1580 E:1582 ||| .
New  ||| S:1582 E:1586 ||| JJ
surrogate  ||| S:1586 E:1596 ||| JJ
markers  ||| S:1596 E:1604 ||| NNS
are  ||| S:1604 E:1608 ||| VBP
needed  ||| S:1608 E:1615 ||| VBN
to  ||| S:1615 E:1618 ||| TO
assess  ||| S:1618 E:1625 ||| VB
disease  ||| S:1625 E:1633 ||| NN
activity ||| S:1633 E:1641 ||| NN
.  ||| S:1641 E:1643 ||| .
Glucocorticoids  ||| S:1643 E:1659 ||| NNS
are  ||| S:1659 E:1663 ||| VBP
the  ||| S:1663 E:1667 ||| DT
cornerstone  ||| S:1667 E:1679 ||| NN
of  ||| S:1679 E:1682 ||| IN
treatment  ||| S:1682 E:1692 ||| NN
and  ||| S:1692 E:1696 ||| CC
cytotoxic  ||| S:1696 E:1706 ||| JJ
drugs  ||| S:1706 E:1712 ||| NNS
are  ||| S:1712 E:1716 ||| VBP
frequently  ||| S:1716 E:1727 ||| RB
used  ||| S:1727 E:1732 ||| VBN
as  ||| S:1732 E:1735 ||| IN
steroid  ||| S:1735 E:1743 ||| JJ
sparing  ||| S:1743 E:1751 ||| JJ
agents ||| S:1751 E:1757 ||| NNS
.  ||| S:1757 E:1759 ||| .
